A new global consensus on integrated skin care has been published with the stated goal of optimizing aesthetic outcomes across dermatologic treatment pathways.

The consensus, reported by Dermatology Times, addresses a persistent gap in clinical practice: aesthetic considerations often sit separate from medical dermatology workflows, and treatment sequencing rarely follows a shared framework. The document brings international expert opinion together in an effort to change that.

What problem does the consensus target?

Integrated skin care, as framed by the agreement, means coordinating medical, surgical and aesthetic interventions rather than treating each in isolation. Patients presenting for inflammatory disease management, for example, frequently have concurrent aesthetic concerns, and the order in which therapies are delivered can affect both tolerability and final cosmetic results.

The consensus responds to wide variation in how clinicians combine:

• Topical and systemic medical therapies
• Energy-based device treatments
• Injectables and other procedural interventions
• Maintenance and skin-care regimens

By defining shared principles for sequencing and combining these modalities, the authors aim to give practitioners a reproducible reference point where none previously existed at a global level.

Why a consensus rather than a trial?

Consensus documents do not generate new efficacy data. Instead, they synthesize available evidence and expert judgment into practical guidance — a standard approach when randomized comparative data across combined treatment pathways are sparse. The reported agreement follows that model, positioning itself as a framework clinicians can apply while formal comparative studies continue to accumulate.

This distinction matters for readers evaluating the strength of the recommendations. Manufacturer claims and single-arm observations often drive aesthetic practice; a structured expert consensus offers a step above anecdote, but it remains below the evidence class of controlled trial data.

Who is the intended audience?

The document targets clinicians who manage patients across the medical–aesthetic interface: dermatologists, aesthetic practitioners and allied providers involved in treatment planning. For practices that already combine modalities, the consensus offers a benchmarking tool; for those that keep medical and aesthetic services separate, it presents an argument — and a structure — for closer integration.

What comes next?

As Dermatology Times reports, the consensus is positioned as a starting point rather than a final word. Its authors anticipate that adoption in routine practice, together with subsequent research on combined treatment sequencing, will refine the recommendations over time — and define whether integrated skin care measurably improves aesthetic outcomes.